Wet AMD

At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.

Investigators from Thailand took a close look at retinal fluid fluctuations in Thai patients with wet age-related macular degeneration (AMD) and devised a better way to measure the fluctuations in the central subfield thickness (CST).

Treatment with faricimab in patients with neovascular AMD achieved improvements in the visual acuity, central subfield thickness, and pigment epithelial detachments.

At ASRS in New York City, New York, Justis Ehlers, MD, presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.

A team of investigators from Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.

Rahul Khurana, MD, offers updates and details about the Aaviate study, which is investigating a possibly once-and-done gene therapy option for macular degeneration via suprachoroidal drug delivery.

Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.

Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.

Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.

According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.

While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.

The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.

Biogen and Samsung Bioepis announce the launch of ranibizumab-nuna and detail when the ophthalmic biosimilar will be available for retina specialists.

Outlook Therapeutics initially filed the BLA in March or the use of bevacizumab-vikg in the treatment of wet AMD. The company said it will re-submit a revised BLA by September.

The data presented at ARVO showed single subcutaneous doses of D-4517.2 were safe, well-tolerated in healthy subjects.

According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.

The Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Colorado, revealed a variety of advancements in technology, pivotal trials and clinical trial design.

The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.

The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

The implant achieves impressive efficacy and reduces treatment burden.

Taiichi Hikichi, MD, counteracted the potential inflammatory effect of brolucizumab by combining its administration with a sub-Tenon’s capsule injection of triamcinolone acetonide.

Firas M. Rahhal, MD, discusses concerns of using repackaged IV bevacizumab for the treatment of wet AMD.

The first FDA-approved bispecific antibody for the eye targets two leading causes of vision loss.

Reducing the treatment burden is a prime goal for emerging AMD therapies.